Jon Hepple

Jon joined Oxford Science Enterprises in July 2020 and advises the Life Sciences team, bringing over 20 years of investment experience from across the Life Science industry.

Jon is also a Partner at Rosetta Capital, a Venture Capital firm focused on the life science and medical technology sectors, which he co-founded in 2009.

He started his investment career at Rothschild Asset Management before co-founding BioScience Managers in 2001. Jon also served as a Partner at Seroba Life Sciences and has held a number of portfolio Board director roles, including Aprea Therapeutics, Covagen AG, Opsona Therapeutics, Catalyst Biosciences, Glycomimetics, NovImmune, Carrick Therapeutics and Mission Therapeutics.

Jon has a PhD in Cancer Research from the University of Cambridge and a BA in Biology from the University of Oxford.